Neurology

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start ADAS-Cog13 difference: −5.43…

4 months ago

C8 Health Raises $12M Series A for the Healthcare Industry’s First AI-Powered, Best Practices Implementation Platform

The healthtech company is already addressing care inconsistency at over 100 hospitals in the United States NEW YORK, July 30,…

4 months ago

Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search Developed in collaboration…

4 months ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label…

4 months ago

Neu Health Launches in U.S., Supported by FDA Clearance for Parkinson’s Tremor Measurement

Delivering precision neurology via smartphone, Neu Health is built on the Oxford Discovery Cohort, one of the world's largest longitudinal…

4 months ago

Creyos Featured in Alzheimer’s Research at AAIC 2025

Findings from Western University, QIMR Berghofer, and Rotman Research Institute underscore the power of Creyos in detecting early risk, validating digital…

4 months ago

Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs…

4 months ago

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA…

4 months ago

Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke

The Phase 3 clinical trial of sovateltide, RESPECT-ETB, is expected to enroll over 500 patients with a primary endpoint of…

4 months ago

Qynapse Releases Data Highlighting the Accuracy of QyScore® and Predictive performance of QyPredict® for Disease Progression in preclinical Alzheimer’s Disease

TORONTO, July 28, 2025 /PRNewswire/ -- Qynapse, a technology company using AI to enhance the quantification and predictive capabilities of imaging…

4 months ago